Drug profile · INN
pegfilgrastim-cbqv
UDENYCA
pegfilgrastim-cbqv (UDENYCA) is a granulocyte colony stimulating factor receptor agonist. Associated with Coherus Oncology. Route of administration: injection. Current US regulatory status: approved.
Drug details — pegfilgrastim-cbqv
- US status
- approved
- Class
- —
- Route
- INJECTION
- Patents
- 3
- Programs
- 0
- Data quality
- 0.89
Quick answer
pegfilgrastim-cbqv (UDENYCA) is a granulocyte colony stimulating factor receptor agonist. Associated with Coherus Oncology. Route of administration: injection. Current US regulatory status: approved.
Key facts
Mechanism of action
Granulocyte colony stimulating factor receptor agonist
Primary target: Granulocyte colony-stimulating factor receptor
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
Related & competitor drugs
Related patents
Frequently asked questions
What is pegfilgrastim-cbqv?
pegfilgrastim-cbqv (UDENYCA) is a granulocyte colony stimulating factor receptor agonist. Associated with Coherus Oncology. Route of administration: injection. Current US regulatory status: approved.
What is the brand name for pegfilgrastim-cbqv?
UDENYCA is a marketed brand name for pegfilgrastim-cbqv. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of pegfilgrastim-cbqv?
pegfilgrastim-cbqv has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.